FDA Orange Book · active-ingredient family
Abacavir sulfate; lamivudine; zidovudine
Abacavir sulfate; lamivudine; zidovudine is approved as 1 brand and 1 generic application in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:TRIZIVIR · NDA 021205
1
Brand (NDA)
1
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| TRIZIVIRRLD | VIIV HLTHCARE | NDA 021205 | — | Nov 14, 2000 |
Generic (ANDA) products (1)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | LUPIN | ANDA 202912 | — | Dec 05, 2013 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Abacavir sulfate; lamivudine; zidovudine — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
